These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 22258336)
41. Aldosterone and Mineralocorticoid Receptors-Physiology and Pathophysiology. Funder JW Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492512 [TBL] [Abstract][Full Text] [Related]
42. Sleep apnea, aldosterone, and resistant hypertension. Pimenta E; Calhoun DA; Oparil S Prog Cardiovasc Dis; 2009; 51(5):371-80. PubMed ID: 19249443 [TBL] [Abstract][Full Text] [Related]
43. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Funder JW Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342 [TBL] [Abstract][Full Text] [Related]
45. Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases. Queisser N; Schupp N Free Radic Biol Med; 2012 Jul; 53(2):314-27. PubMed ID: 22609249 [TBL] [Abstract][Full Text] [Related]
46. Inducible Knock-Down of the Mineralocorticoid Receptor in Mice Disturbs Regulation of the Renin-Angiotensin-Aldosterone System and Attenuates Heart Failure Induced by Pressure Overload. Montes-Cobos E; Li X; Fischer HJ; Sasse A; Kügler S; Didié M; Toischer K; Fassnacht M; Dressel R; Reichardt HM PLoS One; 2015; 10(11):e0143954. PubMed ID: 26605921 [TBL] [Abstract][Full Text] [Related]
47. Role of aldosterone blockade in resistant hypertension. Egan BM; Li J Semin Nephrol; 2014 May; 34(3):273-84. PubMed ID: 25016399 [TBL] [Abstract][Full Text] [Related]
48. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Goodfriend TL; Calhoun DA Hypertension; 2004 Mar; 43(3):518-24. PubMed ID: 14732721 [TBL] [Abstract][Full Text] [Related]
49. Aldosterone breakthrough from a pharmacological perspective. Mogi M Hypertens Res; 2022 Jun; 45(6):967-975. PubMed ID: 35422512 [TBL] [Abstract][Full Text] [Related]
50. Resistant hypertension: identifying causes and optimizing treatment regimens. Trewet CL; Ernst ME South Med J; 2008 Feb; 101(2):166-73. PubMed ID: 18364619 [TBL] [Abstract][Full Text] [Related]
51. Drug mechanisms to help in managing resistant hypertension in obesity. Jansen PM; Danser JA; Spiering W; van den Meiracker AH Curr Hypertens Rep; 2010 Aug; 12(4):220-5. PubMed ID: 20532698 [TBL] [Abstract][Full Text] [Related]
52. Aldosterone, organ damage and dietary salt. Catena C; Colussi G; Sechi LA Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):922-8. PubMed ID: 23803228 [TBL] [Abstract][Full Text] [Related]
53. Aldosterone receptor antagonists: current perspectives and therapies. Guichard JL; Clark D; Calhoun DA; Ahmed MI Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977 [TBL] [Abstract][Full Text] [Related]
54. Translational research goes both ways: lessons from clinical studies. Funder JW Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):526-9. PubMed ID: 18307755 [TBL] [Abstract][Full Text] [Related]
55. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Bender SB; McGraw AP; Jaffe IZ; Sowers JR Diabetes; 2013 Feb; 62(2):313-9. PubMed ID: 23349535 [TBL] [Abstract][Full Text] [Related]
56. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Nishiyama A Hypertens Res; 2019 Mar; 42(3):293-300. PubMed ID: 30523293 [TBL] [Abstract][Full Text] [Related]